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Abstract:  
 
 
PI3K is critical for the normal function of the immune system, however dysregulated PI3K 
mediated signalling has been linked to the development of many immune mediated 
pathologies. This review describes current progress in the development of isoform-specific 
PI3K inhibitors that hold promise for the treatment of hematopoietic malignancies as well as 
for inflammatory and autoimmune diseases. A SH2-domain containing inositol-5-phosphatase 
(SHIP) is a regulator of PI3K signalling, and is also discussed as a potential drug target for 
immunomodulation and the treatment of leukemia. Recent progress has been made in the 
development of small molecule compounds that potently and selectively modulate SHIP 
activity and hence provide a novel mechanism to alter PI3K mediated signalling.  
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Introduction 
 
Activation of class 1 phosphoinositide 3-kinase (PI3K) occurs following ligation of a plethora 
of leukocyte receptors that are responsible for innate and adaptive immune responses [1-3]. 
Activation of PI3K results in the addition of a phosphate group to its lipid substrate PI(4,5)P2, 
forming PI(3,4,5)P3 in the cell surface membrane. PI(3,4,5)P3 initiates a variety of signalling 
cascades by interaction with pleckstrin homology (PH) domain containing proteins, most 
notably the serine kinase Akt [4].  
 
Class 1A isoforms (PI3Kα, PI3Kβ and PI3Kδ) are activated by receptor tyrosine kinases, 
whilst the Class 1B isoform PI3Kγ is activated following GPCR ligation.  However, these 
definitions are proving less rigid than previously thought. For example, PI3Kβ has been 
shown to signal downstream of GPCR activation [5], whilst activation of the Class 1B 
isoform PI3Kγ has been reported by receptor tyrsosine kinases and TLR/IL-1Rs [6]. PI3Kγ 
has also been reported to participate in T-cell-receptor signalling [7]. The PI3Kα and PI3Kβ 
isoforms appear to have a broad tissue distribution, while PI3Kδ and PI3Kγ are primarily 
expressed in leukocytes.  Studies using mice in which the genes encoding PI3Kδ or PI3Kγ 
have been either altered to encode kinase-inactive mutants (e.g. PI3KδD910A mice) or deleted, 
have revealed that PI3Kδ and PI3Kγ have non-redundant but often co-ordinated, functions in 
B cells, T cells, NK cell, neutrophils, mast cells and dendritic cells [1-3,8,9].  Indeed, when 
the immune system of these mice is challenged they exhibit severely defective responses to 
infection [1-3].  
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Development of PI3K inhibitors to target the immune system: lessons from PI3Kδ 
The strong evidence of a role of dysregulated PI3Kγ and PI3Kδ in immune-mediated 
pathologies, has prompted intense efforts to develop selective inhibitors of these isoforms. 
The first compounds to block PI3K–the natural product wortmannin and Lilly’s Ly294002 
were reported in the early 1990’s and served as useful experimental tools to research the PI3K 
pathway [2]. This is evidenced by nearly 6000 PUBMed hits for Ly294002 alone.  However, 
the usefulness of wortmannin and Ly294002 both as research tools and potential drugs was 
tempered by their broad targeting of all PI3K isoforms and off-target effects [10]. However, 
the simple planar structure of Ly294002 (Figure 1) has aided the design of more selective 
pan-PI3K and isoform specific inhibitors. In particular, crystal structures of PI3Ks bound to 
Ly294002, have facilitated huge advances in the design of PI3K inhibitors which utilize the 
regions of the ATP binding pocket to achieve greater potency and selectivity as well as 
reduced toxicity  [11-13] 
 
Compounds that selectively inhibit PI3Kγ have been identified, with a series of compounds 
designed by Merck Serono SA based on the thiazolidinedione scaffold. One of these, AS-
605240 (Figure 1), exhibited superior potency compared to related compounds, can be 
administered orally and has high cell membrane permeability [14]. However, the subsequent 
development of PI3Kγ inhibitors for the treatment of inflammatory disorders in humans has 
been largely disappointing. This is most likely due to the selectivity achieved for PI3Kγ over 
other class 1A PI3K isoforms, being insufficient to avoid off-target effects.  In contrast, the 
development and implementation of inhibitors which target the PI3Kδ isoform has proven 
more successful. The discovery of the quinazolinone purine series, exemplified by the ICOS 
compound  IC-87114 (Figure 1) demonstrated that the design of isoform selective PI3K 
inhibitors with at least 50-fold potency over other isoforms was possible to achieve [15]. 
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In 2006 several members of ICOS Corporation formed a spin-out company, Calistoga 
Pharmaceuticals. Calistoga developed CAL-101, a PI3Kδ specific inhibitor that exhibits 40-
300 fold selectivity over other PI3K isoforms.  CAL-101 which was acquired by Gilead in 
February 2011 and recently renamed GS-1101) has shown success in clinical trials for 
treatment of B cell malignancies where it causes rapid lymph node shrinkage and 
lymphocytosis.  CAL-101 displays a dual mechanism of action whereby it both decreases cell 
survival and reduces interactions that retain CLL cells in protective tissue microenvironments 
[16,17]. This inhibitor has therefore demonstrated an essential role for PI3Kδ in constitutive 
PI3K signaling that is required for the survival of malignant B cells. Oncogenic mutations of 
components of the PI3K signaling pathway are infrequent in B cell malignancies. A potential 
mechanism for PI3K activation in this setting is tonic antigen-independent B cell receptor 
(BCR) signaling that requires PI3Kδ for the transduction of proliferation and survival signals.   
 
Inhibition of the PI3Kδ isoform for the treatment of inflammatory disorders is also being 
explored. Specifically, CAL-101 and CAL-263 have entered clinical trials for allergic rhinitis 
(Table 1). In addition, patents have been filed by several other companies (Amgen, Intellikine 
and Incyte) describing PI3Kδ inhibitors and the majority are based on the same basic 
pharmacophore identified by ICOS [18]. However, additional scaffolds have now been 
reported by several companies; almost all of these are with intended indications against B cell 
lymphomas [18]. 
 
The non-redundant and often coordinated roles of PI3Kδ and PI3Kγ in immune cell function 
described earlier, provide a rationale for targeting both isoforms simultaneously with a single 
compound. TargeGen described two diaminopteridine-diphenol-based compounds with good 
selectivity for PI3Kγ and PI3Kδ that showed early promise in animal models of myocardial 
ischemia as well as asthma and chronic obstructive pulmonary disease [19,20]. The TargeGen 
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compounds did not progress beyond phase I/II clinical trails.  Infinity and Intellikine are 
currently in pre-clinical trials with IPI-145 (Table 1), the only PI3Kγ/δ inhibitor currently in 
development for the treatment of inflammatory disease [18].   
 
There is an increasing appreciation of a role for PI3K in the immune system including 
cooperation with PI3Kδ in the generation of reactive oxygen species (ROS) in neutrophils in 
response to fungal infection or immune complexes [21,22].   This provides a rationale for 
targeting PI3Kβ as well as PI3K in the treatment of inflammatory disorders. Indeed, 
compounds with dual selectivity for PI3Kand PI3K have been reported suggesting that this 
approach is feasible [13]. However, caution should be applied to the use of PI3Kβ inhibitors 
in inflammatory disorders due to the described role of PI3Kβ in thrombus formation and 
circulatory homeostasis [23].    
 
SHIP-1 as an alternative target for modulation of PI3K signaling. 
 
Role of SHIP in the immune system 
The development of isoform specific PI3K inhibitors for inflammatory disease, particularly 
toward PI3K, has been disappointing. This has lead to the search for alternative targets with 
which to modulate PI3K signalling specifically in the immune system. In this regard, attention 
has recently focussed on the lipid phosphatase SH2-domain containing inositol-5-phosphatase  
(SHIP), which de-phosphorylates PI(3,4,5)P3 at the D5 position of the inositol ring to create 
PI(3,4)P2. Multiple forms of SHIP have been reported, but the 145 kDa SHIP-1 (Figure 2) is 
a particularly ideal target for development of potential therapeutics for treating immune 
disorders. This is because its hematopoietic-restricted expression would limit the impact of 
SHIP-1 targeted drugs to the immune system. One would predict for example, that activators 
of SHIP-1 would lead to a reduction of cellular PI(3,4,5)P3 levels and hence, mimic the effect 
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of PI3K inhibitors.  SHIP-1 was initially considered as a negative regulator of PI3K 
signalling.  However, the SHIP-1 product PI(3,4)P2 is itself recognized by some PH domain-
containing proteins [24]. Thus SHIP-1 can act as a molecular ‘switch’, re-directing PI3K 
signalling away from PI(3,4,5)P3-dependent effector proteins, towards proteins which bind 
exclusively or partially to PI(3,4)P2. 
 
SHIP-1 is recruited to the surface membrane following ligation of a variety of receptors 
including, chemokine, antigen, co-stimulatory and cytokine receptors as well as IgG 
engagement [25]. SHIP-1 knockout mice have proven invaluable in identifying the crucial 
role of SHIP-1 in the regulation of mast cell degranulation, BCR signaling and autoantibody 
production, dendritic cell function and NK cell cytolytic function (Table 2). SHIP-1 also 
regulates TLR signaling [26,27,28], lymphocyte polarization and migration [29] and has a 
pivotal role in regulating the balance between pro-inflammatory and anti-inflammatory 
myeloid and lymphoid cells [30,31].   
 
The Role of SHIP-1 in leukemia  
Over-activation of PI3K-dependent signalling cascades is a common occurrence in many 
human cancers [32].  The lipid phosphatase PTEN which also negatively regulates PI(3,4,5)P3 
accumulation by de-phosphorylating the D3 position of the inositol ring, is a well 
characterized tumour suppressor gene [33]. Likewise, evidence for mutations of SHIP-1 have 
also been shown in acute lymphoblastic leukaemia [34] and in acute myeloid leukaemia [35].  
SHIP-1 is targeted by miR-155 in B cells, with high levels of miR-155 and reduced SHIP-1 
expression linked to the development of acute lymphoblastic leukaemia in mice [36]. miR-
155 levels were also found to be significantly increased in human patients with diffuse large 
B cell lymphoma [37]. The loss of SHIP-1 has been shown to promote the development of 
erythroleukemia, with SHIP-1 identified as a target gene of the oncogene fli-1 [38]. The loss 
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of SHIP-1 has been shown to promote the development of erythroleukemia, with SHIP-1 
identified as a target gene of the oncogene fli-1 [38]. The role of SHIP-1 as a tumour 
suppressor is also evident in  the ability of SHIP-1 to restrict myeloid suppressor cells and 
regulatory T cells [30,39]. Therefore the loss of SHIP-1 expression/ function may lead to 
increased suppression of T-cell mediated anti-tumour immunity.  Indeed, in murine pancreatic 
cancer SHIP-1 expression was shown to be reduced in splenocytes which also correlated with 
an increase in myeloid suppressor cell numbers [40]. Decreased SHIP-1 expression has also 
been shown in myelodysplastic syndrome progenitor cells, where over-expression of SHIP-1 
inhibited myeloid leukemic growth [41]. 
 
The role of SHIP-1 in leukemia however, appears more complex than initially thought. For 
example, SHIP-1 was shown not to act as a tumour suppressor in myeloma cells [42]. The use 
of a small molecule SHIP-1 inhibitor demonstrated that catalytically active SHIP-1 is required 
for the survival of multiple myeloma cells [43] and that therefore, in certain cases, SHIP-1 
actually supports cancer cell survival. This would be consistent with increased levels of the 
SHIP-1 enzymatic product PI(3,4)P2 promoting Akt activation and survival/proliferation [44]. 
Indeed another group has shown that SHIP-1 inhibits CD95/Fas-mediated apoptosis of T cells 
[45].  
 
Pharmacological Targeting of SHIP  
 
Allosteric SHIP-1 activators: 
The identification and description of an activator of SHIP-1, termed pelorol, was first 
described in 2005 and was derived from the marine invertebrate Dactylospongia elegans [46]. 
Aquinox Pharmaceuticals designed more potent synthetic analogies AQX-MN100 and AQX-
016A (Figure 1) which along with  PI(3,4)P2, were shown to allosterically enhance catalytic 
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activity by binding to the C2 domain of SHIP-1 (Figure 2). AQX-016A and AQX-MN100 
showed potent inhibition of immune cell activation in vitro and were anti-inflammatory in 
vivo using mouse models of endotoxemia and acute cutaneous anaphylaxis [47]. Intriguingly, 
these SHIP-1 activating compounds increased apoptosis of multiple myeloma cells in vitro 
and when used in combination with bortezomib (an established multiple myeloma treatment) 
proved more effective at inhibiting cancer cell proliferation than bortezomib alone [48]. 
Aquinox Pharmaceuticals are developing SHIP-1 activating compounds based on the structure 
of pelorol, to be used in inflammatory disorders. AQX-1125 is the most advanced and  passed 
Phase 1 clinical trials in 2011, with Phase IIa clinical studies initiated in late 2011 for the 
treatment of mild and moderate asthma (Table 1) 
 
SHIP-1 inhibitors 
A novel small molecule selective inhibitor of SHIP-1, termed 3 α-aminocholestane (3AC, 
Figure 1) has also recently been identified using high throughput screening, although the site 
of action is currently unclear [43]. Consistent with observations from SHIP-1 deficient mice, 
treatment of mice with 3AC led to increased numbers of myeloid suppressor cells and reduced 
ability of peripheral lymphoid tissues to prime myeloid-associated responses and protected 
against Graft-versus-host disease [43]. The inhibition of SHIP-1 using pharmacological 
compounds may therefore offer the potential to aid transplant acceptance in patients 
undergoing transplant surgery.  3AC also increased levels of granulocytes, red blood cells, 
neutrophils and platelets in mice and could therefore, have potential to improve blood cell 
number in patients with myelodysplastic syndrome or myelosuppressive infection.   
 
Remarkably, SHIP-1 inhibition using 3AC induced the apoptosis of human AML cell lines 
which is consistent with SHIP-1 being anti-apoptotic under some circumstances [43]. Further 
studies showed that 3AC inhibited multiple myeloma cell growth in a tumour xenograft 
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model in mice [49]. Since both substrate [PI(3,4,5)P3] and  product [PI(3,4)P2] of SHIP-1 
have been shown to influence Akt activation and cell survival, this may explain in part, why 
both activators and inhibitors of SHIP-1 have shown efficacy against leukemic cells [50]. 
 
SHIP-2 inhibitors 
SHIP-2 shares 35% homology with SHIP-1, and is thought to be involved in type-2 diabetes 
and obesity [51]. Its ubiquitous expression means that it is also expressed in leukocytes and 
one concern is that inhibition of SHIP-1 will be compensated for by SHIP-2. In recent years 
progress has been made in the development of small molecule compounds which inhibit the 
catalytic activity of SHIP-2 [52]. Another group has identified a novel biphenyl 2,3’4,5’,6-
pentakisphosphate [BiPh(2,3',4,5',6)P5], which showed potent inhibition of SHIP-2 catalytic 
activity [53]. This biphenyl compound is however, not cell permeable and does not possess 
drug-like properties. Nevertheless, the crystal structure of the phosphatase domain of SHIP2 
bound to BiPh(2,3',4,5',6)P5 has recently been reported. Molecular dynamics simulations 
suggest that when BiPh(2,3',4,5',6)P5 binds to SHIP2, a flexible loop folds over and encloses 
the ligand [54]. Compounds targeting such a closed conformation might therefore deliver 
SHIP2-specific drugs. Recently, pan-SHIP-1/2 inhibitors have been reported to kill multiple 
myeloma cells [49]. The identification of both pan–SHIP and SHIP-2 inhibitors therefore 
provides a useful tool in the identification of the less well-characterized role of SHIP-2 in 
immune cell function.    
 
Summary 
The β, γ and δ isoforms of PI3K have important non-redundant roles in multiple cells of the 
immune system. Consequently alterations of the PI3K signaling pathway can lead to 
inflammatory and autoimmune disorders as well as leukemia. This, together with growing 
appreciation of the crystal structure of the catalytic isoforms which help define the structure-
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activity rules for obtaining selectivity, will spur the continued design and development of 
improved PI3K inhibitors.  These offer opportunities to manipulate the PI3K signaling 
network in immune cells for inflammation and transplantation as well as cancer. The latter 
may include non-leukemic cancers, given the up-regulation of PI3Kγ and PI3Kδ in some 
forms of non-immune cell malignancies [32,55,56]. One concern would be that it might be 
difficult to avoid effects on the immune system that could impair the endogenous anti-tumor 
response.  
 
The difficulties of developing PI3Kγ inhibitors with sufficient selectivity over PI3K isoforms 
has in part, led to the exploitation of endogenous and leukocyte-restricted regulators of PI3K 
signaling, namely the lipid phosphatase SHIP-1. Small molecule regulators of this protein 
have shown early promise in inflammatory, transplantation and cancer settings, and are 
currently in phase I clinical trials to evaluate the safety, tolerability and pharmacokinetics 
(Table 1). However, the targeting of SHIP-1 (particularly with inhibitors), is not without its 
problems. For example, SHIP-1 deficiency leads to a number of pathologies including fibrotic 
lung disease [57], osteoporosis [58] and the development of Crohn’s disease-like ileitis [59]. 
Another point to take into account when pharmacologically targeting SHIP-1, is the fact that 
SHIP-1 has important non-catalytic functions [60]. Therefore inhibition of the catalytic site of 
SHIP-1 may not be sufficient to inhibit SHIP-1 mediated modulation of PI3K activity in all 
cases.  
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Figure Legends: 
 
Figure 1: Chemical Structures of PI3K inhibitors and SHIP-targeting 
compounds. 
 
Figure 2. Structure of SHIP-1 
SHIP-1 possesses a centrally located 5’ phosphatase catalytic domain. A SH2 
domain at the N-terminus and NPXY motifs at the C-terminus [25]. SHIP also 
has a C2 domain adjacent to the catalytic domain which, when bound to 
PI(3,4)P2, acts to allosterically enhance the catalytic activity of SHIP [47].  
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Table 1. Clinical trials status of PI3K and SHIP-1 targeting compounds for 
the treatment of inflammatory disorders  
 
 
Compound Company Target Phase Status Condition Reference 
CAL-101 Gilead Sciences PI3Kδ I Completed Allergic 
Rhinitis 
http://clinicaltrials
.gov/ct2/show/NC
T00836914 
CAL-263 Gilead Sciences PI3Kδ I Completed Allergic 
Rhinitis 
http://clinicaltrials
.gov/ct2/show/NC
T01066611 
IPI-145 Infinity and 
Intellikine 
PI3Kδ/γ I Initiated Inflammatory 
disorders 
http://www.intelli
kine.com/pipeline
/ipi145.html 
AQX-1125 Aquinox 
Pharmaceuticals 
SHIP-1 IIa Initiated Asthma http://www.aqxph
arma.com/content
/aquinox-
pharmaceuticals-
initiates-two-
phase-iia-clinical-
studies-airway-
inflammation 
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Table 2.  Impact of SHIP-1 Gene Targeting on Leukocytes 
 
Cell 
Type 
Phenotype of SHIP-1 KO 
Mast cell Degranulation with IgE stimulation alone [61] 
 
T cell 
 
 
 
 
Basophils 
Increased regulatory T cell differentiation, decreased Th17 development 
[30] 
Enhanced Th1 differentiation and CD8 cytotoxic activity. Decreased Th2 
differentiation [62]  
 
SHIP
-/-
 mice show increased Th2 skewing due to increased IL-4 secretion 
from basophils [31]) 
 
B cell Btk membrane association increased. Hyper-responsive to cross-linking of 
BCR [63] 
Loss of anergy, production of auto-antibodies [64] 
 
Myeloid 
cell 
Increased myeloid suppressor cell numbers [39] 
Increased M2 macrophage skewing (indirect mechanism via increased IL-4 
secretion from basophils) [65] 
Increased ratio of PI(3,4,5)P3 to PI(3,4)P2 on phagosomal membrane. 
Decreased early NADPH oxidative activity in phagosomes [66] 
 
Dendritic 
cell 
Enhanced survival and proliferation, but impaired maturation [67] 
Reduced nitric oxide production; SHIP null DC’s suppress T cell 
proliferation [68] 
 
Natural 
Killer cells 
Deficient receptor repertoire. Defective IFNγ secretion. Increase in 
peripheral number. Defective cytolytic function. [69]. 
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